Pulmonary Imaging Software supports distributed viewing.
November 1, 2013 -
Offering optimized workflow and dataflow for high-volume, time-constrained clinical environments, Apollo™ v2.0 identifies objective information to better understand disease subtypes, to interact with results at point of procedure, and to aid in identifying optimal treatment strategies for patients with lung disease. FDA-cleared, CE, CMDCAS, and TGA certified, program enables distributed review of results and provides optimized structured reporting.
|Original Press Release |
VIDA Diagnostics, Inc.
21631 Stevens Creek Blvd.
Cupertino, CA, 95014
VIDA Diagnostics Releases Next Generation Software for Distributed Viewing and Workflow Enhancements
Apollo(TM) 2.0 Released Enhancing Clinical Experience
CHICAGO -- VIDA Diagnostics, a leading provider of quantitative imaging and informatics services to aid diagnosis and treatment planning for patients with pulmonary disease, announces the release of Apollo 2.0, here at the 2013 American College of Chest Physicians (Chest) Conference. The software advance signifies the next generation product expansion of their flagship ApolloŽ pulmonary imaging software platform, introducing distributed review of results, enhancements to structured reporting, and streamlining of the imaging services workflow.
"Incorporation of a more informed imaging solution into the management of the patient with lung disease is a growing necessity for best practices and cost containment," said Kyle Hogarth, MD, Director of Interventional Pulmonology at the University of Chicago. "VIDA's Apollo identifies objective information to better understand disease subtypes, to interact with results at the point of procedure and aid in identifying optimal treatment strategies for the patient with lung disease."
Lung cancer is a public health issue that affects more than 370,000 Americans and represents a $14 billion expense each year, according to the American Lung Association. COPD, also known as emphysema and chronic bronchitis, is the third leading cause of death in the United States and adds $18 billion in annual healthcare spend. Asthma has an annual cost of $56 billion a year in the United States.
The FDA-cleared, CE, CMDCAS and TGA certified, Apollo 2.0 strengthens VIDA's groundbreaking solution for pulmonary image analysis with workflow and dataflow improvements for use in a high volume, time constrained clinical and clinical trial environment. VIDA's pulmonary image evaluation services generate repeatable measurements of lung structure and function aiding the pulmonary physician in determining appropriate treatment strategies. "Clinical use of quantitative imaging information is a partnership between the clinical site and VIDA's service offerings," said Susan A. Wood, Ph.D., president and CEO of VIDA. "Apollo 2.0 extends the reach of our flagship Apollo offering and enables interaction with the quantitative imaging results at the point of care."
VIDA is a leading global quantitative pulmonary imaging services company that drives innovative pulmonary device and pharmaceutical solutions for better patient outcomes. VIDA develops and commercializes pulmonary software services, and is an established leader in quantitative image analysis for major lung disease including COPD, emphysema, lung cancer and asthma. VIDA's vision is to establish quantitative CT methods as the standard of care for screening, diagnosis, staging and treatment of major lung disease. Please visit www.vidadiagnostics.com to learn more about our business.
CONTACT: Rosanna Byersdorfer, Director, Business Operations, VIDA Diagnostics, Inc., 1-866-900-VIDA, email@example.com